A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Sheltowee Medical Device Fund Breaks Escrow Making Its 1st Investment in Embolic Acceleration, LLC

November 12, 2020

Sheltowee Medical Device Fund, LP (SMDF) broke escrow and made its first investment in Embolic Acceleration, LLC (EMBA) of Miramar, FL, recently. The SMDF is a $20M venture fund dedicated to investing in the best and brightest medical devices and entrepreneurs in the “heartland” of the U.S.

Sheltowee Medical Device Fund investment thesis is to target seed and early stage medical device companies in the cardiovascular, orthopedics, and digital wearables market segments, all areas of expertise by the leadership team and Scientific Advisory Board of the fund. The fund will target five investments per year for five years. Each portfolio company will be actively engaged by the Leadership Team and be integrated into an ecosystem of innovation, product development, and product commercialization.

Brian Doughty, SMDF Partner, stated, “These companies must have clear intellectual property value, a clear path to commercialization, and be ready to embrace the DeltaForceTM method.”  This method is a key efficiency driver that has been demonstrated to propel companies through their early, awkward stages faster and more cost-effectively than traditional venture investment models for medical devices. “EMBA scored well on our 15-point structural diligence report and equally well on our 217-point market acceptance risk report,” said Doughty. “We have high expectations of the company,” he added.

“We are excited about what we have been able to accomplish this year in the midst of the turmoil of 2020,” stated Dobson. “We expect to fully capitalize the fund shortly and expand our impact,” he added. Dobson further stated, “We are thrilled we were able to break escrow, make our first investment, create such an outstanding Scientific Board of Advisors this year.  We expect to make one more investment before year end. And, 2021 is shaping up to be a great year for Sheltowee.”

The SMDF is expected to be fully capitalized in early 2021. Investors interested in information should contact Eric Dobson, listed below.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.

By using this website you agree to accept Medical Device News Magazine Privacy Policy